Uncategorized

Estrigenix Therapeutics to Attend The Menopause Society Meeting

MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier organization for health professionals with Estrigenix Therapeutics to Attend The Menopause Society Meeting

Estrigenix welcomes new employees

Estrigenix Therapeutics welcomed two new employees this summer, Ms. Elaina Milkie and Dr. Dulanjali Thennakoon. Ms. Elaina Milkie graduated with B.S. from the University of Wisconsin-Milwaukee (UWM) in May 2023, double majoring in Psychology and Biological Sciences. Elaina worked part time with Estrigenix in spring 2023 while completing her degree and transitioned to full time Estrigenix welcomes new employees

Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics was one of five Wisconsin-based companies awarded matching funding from the SBIR Advance Phase 1 program funded by the Wisconsin Economic Development Corporation. The SBIR Advance program provides assistance to companies in the process of completing a project in the federal Small Business Innovation Research (SBIR) program. feedback and reviewed multiple proposals from Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston

MILWAUKEE (June , 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the Precision Drug Discovery & Preclinical (PDDP) Summit 2023 in Boston. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery of Selective Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston

Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast

MILWAUKEE (May 16, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was recently featured on the podcast FemTech Focus hosted by Brittany Baretto, PhD. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Dr. Baretto regarding Estrigenix’s first-in-class therapeutics to treat and prevent hot flashes Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast

Estrigenix Therapeutics’ Scientific Advisor, Dr. Pauline Maki Ph.D., Receives Health Education Visionary Award

Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce that Dr. Pauline Maki Ph.D., a member of our Scientific Advisory Board, is receiving the Health Education Visionary Award from The Society for Women’s Health Research (SWHR) at their 2003 Annual Awards Gala held in Washington Estrigenix Therapeutics’ Scientific Advisor, Dr. Pauline Maki Ph.D., Receives Health Education Visionary Award

Estrigenix Therapeutics, Inc.’s Chief Scientific Officer Karyn Frick PhD featured in Center for Technology Commercialization

Estrigenix Therapeutics,  Inc.’s chief scientific officer, Karyn Frick PhD was recently featured in Center for Technology Commercialization talking about the process Estrigenix went through to receive Small Business Innovation Research (SBIR) Ready funding. The SBIR Ready program provided feedback and reviewed multiple proposals from Estrigenix before giving Estrigenix the green light for the SBIR Ready Estrigenix Therapeutics, Inc.’s Chief Scientific Officer Karyn Frick PhD featured in Center for Technology Commercialization

Karyn Frick, Ph.D Featured on “Beyond the Paper Gown” Podcast

MILWAUKEE (Dec. 8, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was recently featured on the podcast Beyond the Paper Gown™ hosted by Mitzi Krockover, MD. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Dr. Krockover regarding Estrigenix’s first-in-class therapeutics to treat and prevent Karyn Frick, Ph.D Featured on “Beyond the Paper Gown” Podcast

Estrigenix Appoints Patricia Scheller as Executive Chairwoman

MILWAUKEE (Dec. 5, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce Patricia Scheller as its executive chairwoman.    In this role, Scheller will be actively involved in Estrigenix’s business. She will chair the board of directors, act as an advisor to William Donaldson, <strong>Estrigenix Appoints Patricia Scheller as Executive Chairwoman</strong>

Estrigenix Therapeutics, Inc. honored to have presented at Women’s Healthy Aging Innovation Summit 2022 in San Diego

MILWAUKEE (November 16, 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was selected as the winner for the ‘Alzheimer’s & Brain Health’ Category among all presenting companies, for demonstrating the most innovative work in the Alzheimer’s, dementia, and brain health sector. Karyn Frick, Ph.D., chief science <strong>Estrigenix Therapeutics, Inc. honored to have presented at Women’s Healthy Aging Innovation Summit 2022 in San Diego</strong>